1628 related articles for article (PubMed ID: 35760939)
1. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
[TBL] [Abstract][Full Text] [Related]
3. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A
Front Immunol; 2022; 13():846248. PubMed ID: 35432314
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
6. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.
Petrović V; Vuković V; Patić A; Marković M; Ristić M
PLoS One; 2022; 17(2):e0263468. PubMed ID: 35108321
[TBL] [Abstract][Full Text] [Related]
8. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.
Petrović V; Vuković V; Patić A; Marković M; Ristić M
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679901
[TBL] [Abstract][Full Text] [Related]
10. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial.
Hanberg JS; Fu X; Wang X; Patel NJ; Kawano Y; Schiff A; Kowalski EN; Cook CE; Vanni KMM; Guzzo K; Qian G; Bade KJ; Saavedra A; Venkat R; Srivatsan S; Zhang Y; Sparks JA; Wallace ZS
Lancet Rheumatol; 2024 Jan; 6(1):e21-e30. PubMed ID: 38258675
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
13. Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
Isnardi CA; Cerda OL; Landi M; Cruces L; Schneeberger EE; Montoro CC; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; de Los Ángeles Correa M; Rosemffet MG; Abarza VC; Pellet SC; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; Quintana R; de la Vega MC; Kreplak N; Pifano M; Maid P; Pons-Estel GJ; Citera G
J Rheumatol; 2022 Dec; 49(12):1385-1389. PubMed ID: 36182107
[TBL] [Abstract][Full Text] [Related]
14. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
15. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
17. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
[TBL] [Abstract][Full Text] [Related]
19. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.
Batmunkh B; Otgonbayar D; Shaarii S; Khaidav N; Shagdarsuren OE; Boldbaatar G; Danzan NE; Dashtseren M; Unurjargal T; Dashtseren I; Dagvasumberel M; Jagdagsuren D; Bayandorj O; Biziya B; Surenjid S; Togoo K; Bat-Erdene A; Narmandakh Z; Choijilsuren G; Batmunkh U; Soodoi C; Boldbaatar EA; Byambatsogt G; Byambaa O; Deleg Z; Enebish G; Chuluunbaatar B; Zulmunkh G; Tsolmon B; Gunchin B; Chimeddorj B; Dambadarjaa D; Sandag T
PLoS One; 2023; 18(12):e0295167. PubMed ID: 38064430
[TBL] [Abstract][Full Text] [Related]
20. Humoral and T Cell Response to SARS-CoV-2 Vaccination in Patients With Rheumatoid Arthritis.
Isnardi CA; Landi M; Cruces L; Maid P; Calle Montoro C; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; Correa MÁ; Cerda OL; Rosemffet MG; Carrizo Abarza V; Catalan Pellet S; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; De La Vega MC; Citera G; Pons-Estel GJ; Schneeberger EE
Arthritis Care Res (Hoboken); 2024 Jan; 76(1):120-130. PubMed ID: 37605835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
